Revenue
366 thousand
2022 Q4 ·
Fundies. English
SOLIGENIX, INC.
EDGAR172 filing records in this dataset, filed from 1995-08-08 to 2026-08-07. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-975.22%
2022 Q4 · %
Exact inputs and evidence
- Cash and cash equivalents
- 22.9 million Unit_Standard_USD_djtWpoE-m02sAs9CKKOPpw Source
Exact value
22875679 Unit_Standard_USD_djtWpoE-m02sAs9CKKOPpw
- Long-term debt including current maturities
- 0 Unit_Standard_USD_aE1WQ6kH2USLExbVWh2OnQ Source
Exact value
0 Unit_Standard_USD_aE1WQ6kH2USLExbVWh2OnQ
- Shares outstanding
- 21.6 million Unit_Standard_shares_FuS3o286KE6Y95craB6ZVA Source
Exact value
21637479 Unit_Standard_shares_FuS3o286KE6Y95craB6ZVA
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-07.
Financial data available through: 2024-12-31.
Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.
Coverage by financial measure
- Revenue: Multiple units; comparison withheld· newest 2024-12-31
- Operating income: Multiple units; comparison withheld· newest 2024-12-31
- Net income: Multiple units; comparison withheld· newest 2024-12-31
- Operating cash flow: Multiple units; comparison withheld· newest 2024-12-31
- capital expenditure: No compatible figures in this window
- Total assets: Multiple units; comparison withheld· newest 2024-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2024-12-31
- Current assets: Multiple units; comparison withheld· newest 2024-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2024-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2021-12-31
- Long-term debt including current maturities: 2 of 11 periods available· newest 2024-12-31
- Shares outstanding: Multiple units; comparison withheld· newest 2024-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
No compatible annual cash generation figures are available for this company.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
172 filings · 6,569 latest values · 6,569 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000812796, 812796, SNGX, edgar:812796
Also known as DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC, SOLIGENIX, INC., SOLIGENIX, INC., Soligenix, Inc., Soligenix, Inc.